Drugs That Distort Organic Acids (Urine) Testing: What to Hold Before Your OAT

What an organic acids urine test actually measures

An organic acids test (OAT) quantifies dozens of small-molecule intermediates of cellular metabolism that are excreted in urine. These metabolites reflect activity in the citric acid cycle, fatty acid beta-oxidation, B-vitamin-dependent enzyme steps, neurotransmitter turnover, and gut microbial and fungal metabolism. Most commercial panels use gas chromatography-mass spectrometry or liquid chromatography-tandem mass spectrometry on a single first-morning urine specimen, with results normalized to urine creatinine to account for hydration.

Because these metabolites sit downstream of specific enzymes, a drug that partially blocks, induces, or bypasses one of those enzymes can shift several markers at once, sometimes in a pattern that resembles an inborn metabolic disorder even though the cause is pharmacologic. This is a long-recognized principle in clinical laboratory interpretation of organic acid profiles, and it is the reason every OAT requisition should list current medications and supplements.

The core answer for this page: a working OAT panel is sensitive to at least a dozen common drug and supplement classes, and the clinically important distinction is not "which drugs interfere" but "which interferences can be avoided by a short hold, and which reflect a drug you should not stop, so the result needs to be interpreted with the medication in mind rather than eliminated by discontinuing it." Antibiotics, antifungals, and supplement loading (B vitamins, carnitine, NAC) are the interferences most amenable to a pre-test hold. Valproic acid, metformin, and SSRIs/SNRIs are interferences you generally manage through documentation and clinical interpretation, not discontinuation, because stopping them carries its own medical risk.

Antibiotics and antifungals: the biggest source of false-negative microbial findings

Broad-spectrum antibiotics suppress the intestinal bacteria and yeast whose metabolic byproducts make up the microbial-marker section of most OAT panels. Markers such as hippurate, benzoate, D-arabinitol, tartarate, and dihydroxyphenylpropionic acid (DHPPA) can fall sharply during or shortly after a course of antibiotics, producing a falsely reassuring "clean" microbial profile even when dysbiosis is present at baseline.

Gut microbial communities do not necessarily return to their pre-antibiotic state quickly. Research on antibiotic-associated microbiome recovery has reported that some commensal bacterial populations remain altered for an extended period after a single course of broad-spectrum therapy, though the specific studies behind this claim require verification against the primary literature before being cited with exact figures, and no controlled study specifically tracking OAT metabolite recovery after antibiotics was available to support a precise day count for this article. In practice, most reference laboratories instruct patients to wait at least two weeks after finishing antibiotics before collecting an OAT specimen, and some clinicians extend this further after fluoroquinolones or combination regimens. This is laboratory operating guidance, not a finding from a controlled trial, and readers should follow their own lab's specific instructions.

Oral antifungals (fluconazole, nystatin, itraconazole) create the mirror-image problem: they can suppress Candida and Aspergillus-associated metabolites (D-arabinitol, tartaric acid, citramalic acid) during treatment, making active fungal overgrowth invisible on the panel. If the clinical question is whether dysbiosis or fungal overgrowth exists, testing while on an antifungal is likely to understate it. A two-week hold before collection is standard laboratory practice.

Valproic acid and other anticonvulsants: a direct metabolite overlap, not a hold candidate

Valproic acid (Depakote) is unusual because it is itself an organic acid. Its hepatic metabolism, through mitochondrial beta-oxidation and omega-oxidation, produces 3-hydroxyglutaric acid, adipic acid, suberic acid, and other dicarboxylic acids that directly overlap with the endogenous markers used to assess fatty acid oxidation. A patient taking valproate will typically show elevated dicarboxylic acids on OAT, a pattern that can otherwise be mistaken for a medium-chain acyl-CoA dehydrogenase (MCAD) deficiency or a carnitine transport defect.

Stopping valproate to get a "cleaner" test result is not appropriate given seizure risk. The correct approach is for the ordering clinician to note valproate use on the requisition and interpret the dicarboxylic acid markers in that context, rather than treating them as evidence of an independent fatty acid oxidation disorder. Carbamazepine and phenytoin induce hepatic drug-metabolizing enzymes and may have a smaller, less well-characterized effect on some detoxification-pathway markers; this effect is worth documenting but is less predictable than valproate's direct contribution.

Acetaminophen, NSAIDs, and aspirin

Acetaminophen (Tylenol) is cleared partly through a pathway that generates a reactive intermediate requiring glutathione for detoxification. Chronic or high-dose acetaminophen use, and in some reported cases acute high-dose use, has been associated with depleted glutathione stores and elevated pyroglutamic acid (5-oxoproline), a marker the OAT panel uses to estimate glutathione status. Because the exact dose-and-timing relationship for a single therapeutic dose has not been clearly established in the material available for this article, the more defensible statement is that recent acetaminophen use of any kind should be disclosed, and a 48-hour hold before collection is a reasonable precaution if pyroglutamic acid is a marker of clinical interest.

Decision framework: stop it, hold it, or just document it?

Not every interfering drug should be paused, and the right choice depends on why the test is being ordered and what happens medically if the drug is stopped. This framework organizes the drugs and supplements discussed on this page into three action categories.

If a drug does not clearly fall into the first row, the default should be "do not stop without asking," not "stop it to be safe."

B vitamins, L-carnitine, and other supplement-driven distortions

High-dose B-vitamin supplementation is one of the more overlooked sources of OAT distortion because each B vitamin feeds directly into a reaction the panel measures.

Vitamin B12 and folate drive the conversion of methylmalonic acid (MMA) to succinyl-CoA. Recent B12 supplementation can suppress MMA and mask a functional B12 deficiency the test would otherwise catch; conversely, abruptly stopping B12 shortly before testing may unmask an elevated MMA reflecting a depleted, but not yet symptomatic, state. A common recommendation is to hold B-complex and standalone B12 supplements for about 72 hours before collection to approximate an unaugmented baseline, though the ideal washout has not been established with controlled data specific to this test.

Riboflavin (B2) is the precursor to FAD, a cofactor for succinate dehydrogenase and related mitochondrial enzymes; high-dose riboflavin, sometimes used for migraine prevention, can lower succinate and glutarate and make mitochondrial function look better than it is. Pyridoxine (B6) affects transamination reactions, and megadoses can suppress tryptophan-pathway markers such as xanthurenate and kynurenate.

L-carnitine supplements directly enhance mitochondrial fatty acid transport, which can reduce the dicarboxylic acid and suberic acid elevations that would otherwise signal impaired beta-oxidation. Clinicians who interpret these panels commonly describe undisclosed supplement use, particularly B-complex, carnitine, and NAC taken together, as one of the most frequent reasons an OAT panel becomes difficult to interpret, since several markers can normalize at once and obscure the metabolic bottleneck the test was ordered to find. Holding carnitine for at least 72 hours before collection is standard practice guidance.

Should you stop metformin, PPIs, or your SSRI before testing?

Metformin inhibits mitochondrial complex I, the first step of the electron transport chain, and patients taking it frequently show an elevated lactate-to-pyruvate ratio on OAT that reflects the drug's mechanism rather than an intrinsic mitochondrial problem. Metformin remains first-line pharmacologic therapy for type 2 diabetes under current American Diabetes Association Standards of Care, and treatment interruptions should be clinically justified rather than made for the convenience of a lab test (ADA Standards of Care, 2024). The practical answer is to keep taking metformin and flag it on the requisition.

Proton pump inhibitors (omeprazole, pantoprazole, esomeprazole) reduce gastric acid and can shift intestinal microbial populations. Long-term PPI use has been linked in observational research to a higher rate of small intestinal bacterial overgrowth, though the specific magnitude of that risk varies across studies and the exact figures require verification before being treated as settled. On OAT this can show up as elevated hippurate, benzoate, or D-lactate. That elevation reflects real, drug-associated changes in gut ecology rather than an analytical artifact, so it should be interpreted as such rather than assumed to represent the patient's unmedicated baseline.

SSRIs and SNRIs affect the neurotransmitter-metabolite section of the panel: 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA), and vanillylmandelic acid (VMA) are downstream metabolites of serotonin, dopamine, and norepinephrine respectively. These medications should not be stopped for testing purposes; the psychiatric risk of discontinuation outweighs the benefit of an unmedicated neurotransmitter-marker baseline. If a true unmedicated baseline is medically necessary for another reason, it generally requires being off the medication for several half-lives, which is measured in weeks for most SSRIs, and that decision belongs to the prescribing clinician, not the testing protocol.

NAC, MCT oil, and other supplement confounders

N-acetylcysteine (NAC) replenishes glutathione directly and can suppress pyroglutamic acid within hours of ingestion. If oxidative stress assessment through pyroglutamic acid is the clinical goal, hold NAC for at least 48 hours.

Medium-chain triglyceride (MCT) oil floods the beta-oxidation pathway with medium-chain fats, generating octanoic and decanoic acid metabolites that are not distinguishable from endogenous production on the assay, which can create a false impression of fatty acid oxidation dysfunction. A 72-hour hold is standard practice guidance.

Activated charcoal taken as a "detox" supplement may bind organic acids in the gut before absorption, potentially lowering gut-derived markers. Cranberry extract and D-mannose, both common for urinary tract infection prevention, contain benzoic acid and arabinose, which directly raise those respective markers. High-dose vitamin C (above roughly 1,000 mg/day) can interfere with oxalate measurement, since ascorbate converts to oxalate both in the body and during sample handling.

The 48-72 hour pre-collection protocol

Hold roughly 72 hours, if your prescriber agrees it is safe: B-vitamin supplements, L-carnitine, NAC, MCT oil, collagen peptides, cranberry extract or D-mannose, high-dose vitamin C.

Hold roughly 48 hours: acetaminophen, NSAIDs, non-prescribed aspirin, activated charcoal.

Hold about two weeks, per your lab's specific instructions: broad-spectrum antibiotics, oral antifungals (fluconazole, nystatin, itraconazole).

Do not stop; document on the requisition instead: valproic acid, metformin, SSRIs/SNRIs, thyroid hormone, insulin, other chronic prescriptions.

These windows reflect common laboratory operating guidance rather than results from controlled trials measuring OAT-specific washout times, and they can differ between Genova, Mosaic, and other vendors. Follow the collection instructions provided by the specific lab your clinician has ordered from, and ask before stopping anything that treats a serious or unstable condition.

Diet also matters in the same window. Apples, grapes, and pears contain arabinose; dark chocolate contains phenylacetic acid; bananas, walnuts, and pineapple contain serotonin precursors that can raise 5-HIAA. A bland diet (rice, eggs, cooked vegetables, plain chicken or fish) for 48 hours before collection removes most of these dietary confounders.

Reading the result: why "normal" differs by lab

OAT reference ranges are not standardized across vendors. Genova Diagnostics, Mosaic Diagnostics (formerly Great Plains Laboratory), and Doctor's Data each use their own methodology and reference population, and results are reported in different units depending on the lab (commonly micromoles or micrograms per milligram of creatinine). A result flagged as normal at one lab could be flagged as borderline at another purely because of differing population norms and cut-points, not because the patient's biology changed.

What counts as clinically significant also depends on the specific marker and the clinical question being asked. Elevated methylmalonic acid, for example, is used as one indicator of functional B12 insufficiency even when serum B12 looks normal, a pattern described in general B12-deficiency literature, though the exact numeric threshold used varies by lab and should come from that lab's own reference range rather than a single fixed cutoff repeated across sources.

Low organic acid levels across multiple categories are not automatically concerning. They can reflect low dietary protein intake, caloric restriction, well-controlled metabolism, or supplement-driven suppression of the markers the test was meant to capture. A flat panel becomes diagnostically suspicious mainly when it does not match the patient's symptoms, which is a prompt to ask whether supplements suppressed the signal rather than a finding on its own.

What is established, what is plausible, and what is not settled

Established: several of these interactions rest on well-characterized pharmacology, valproic acid's direct metabolite overlap with dicarboxylic acid markers, acetaminophen's glutathione-dependent metabolism, metformin's inhibition of mitochondrial complex I, and the general principle that antibiotics and antifungals alter gut and fungal metabolite output. These are grounded in long-standing pharmacology and metabolic disease literature.

Several aspects of organic acid metabolism lack rigorous quantification in the literature on this test: how many days elapse before gut microbial metabolites normalize following antibiotic use, at what dose and timing acetaminophen raises pyroglutamic acid levels, and how substantially PPIs increase bacterial overgrowth risk. While these mechanisms are biochemically sound, the specific numbers cited in earlier versions of this article and in some patient materials have not been traced to verifiable primary sources and have therefore been removed or presented more cautiously rather than stated with unwarranted precision.

Not established from the material available here: a universal numeric threshold for "abnormal" MMA or any other marker that applies across labs, and any specific out-of-pocket price for OAT testing, which varies by lab, ordering clinician, and insurance plan and should be confirmed directly with the testing laboratory before the test is ordered.

When to retest after stopping a drug

Retesting too soon wastes time and money on a result that is still confounded. Retesting too late may miss the clinical window the test was ordered to evaluate. As a general approach: collect the specimen at least two to three weeks after completing antibiotics or antifungals (confirm with your specific lab), about 72 hours after stopping the supplements listed above, and about 48 hours after the last dose of acetaminophen or NSAIDs. Use a first-morning void and freeze the specimen if shipping will be delayed beyond 24 hours, since bacterial overgrowth in an unrefrigerated sample can itself generate artifact organic acids.

If you are unsure whether a specific medication needs to be held, ask the ordering clinician or the testing lab before changing anything, especially for medications that treat seizures, diabetes, depression, anxiety, or thyroid disease. Stopping those medications on your own to "clean up" a lab result carries more risk than the interference itself.